Size Increment During Surveillance in Papillary Thyroid Cancer: Evidence Synthesis and Dose–Response Meta‐Analysis

<h3>Introduction</h3><p dir="ltr">Differentiated thyroid cancer has become a prevalent malignant tumor, particularly papillary thyroid carcinoma (PTC), constituting over 90% of cases. Most PTC lesions are asymptomatic and remain subclinical throughout life, and active sur...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلف الرئيسي: Mohamed Badie Ahmed (10223510) (author)
مؤلفون آخرون: Emad Naem (21363605) (author), Harman Saman (16316283) (author), Abeer Alsherawi (17945291) (author), Asma Syed (14778826) (author), Noora Al‐Abdulla (22502162) (author), Latifa Alkaabi (22502165) (author), Mahmoud A. Zirie (19421317) (author), Suhail A. Doi (9552474) (author)
منشور في: 2025
الموضوعات:
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
_version_ 1864513534082154496
author Mohamed Badie Ahmed (10223510)
author2 Emad Naem (21363605)
Harman Saman (16316283)
Abeer Alsherawi (17945291)
Asma Syed (14778826)
Noora Al‐Abdulla (22502162)
Latifa Alkaabi (22502165)
Mahmoud A. Zirie (19421317)
Suhail A. Doi (9552474)
author2_role author
author
author
author
author
author
author
author
author_facet Mohamed Badie Ahmed (10223510)
Emad Naem (21363605)
Harman Saman (16316283)
Abeer Alsherawi (17945291)
Asma Syed (14778826)
Noora Al‐Abdulla (22502162)
Latifa Alkaabi (22502165)
Mahmoud A. Zirie (19421317)
Suhail A. Doi (9552474)
author_role author
dc.creator.none.fl_str_mv Mohamed Badie Ahmed (10223510)
Emad Naem (21363605)
Harman Saman (16316283)
Abeer Alsherawi (17945291)
Asma Syed (14778826)
Noora Al‐Abdulla (22502162)
Latifa Alkaabi (22502165)
Mahmoud A. Zirie (19421317)
Suhail A. Doi (9552474)
dc.date.none.fl_str_mv 2025-05-08T03:00:00Z
dc.identifier.none.fl_str_mv 10.1002/cnr2.70183
dc.relation.none.fl_str_mv https://figshare.com/articles/journal_contribution/Size_Increment_During_Surveillance_in_Papillary_Thyroid_Cancer_Evidence_Synthesis_and_Dose_Response_Meta_Analysis/30454559
dc.rights.none.fl_str_mv CC BY 4.0
info:eu-repo/semantics/openAccess
dc.subject.none.fl_str_mv Biomedical and clinical sciences
Medical biochemistry and metabolomics
Oncology and carcinogenesis
Health sciences
Epidemiology
active surveillance
dose–response meta-analysis
papillary thyroid cancer
tumor progression
dc.title.none.fl_str_mv Size Increment During Surveillance in Papillary Thyroid Cancer: Evidence Synthesis and Dose–Response Meta‐Analysis
dc.type.none.fl_str_mv Text
Journal contribution
info:eu-repo/semantics/publishedVersion
text
contribution to journal
description <h3>Introduction</h3><p dir="ltr">Differentiated thyroid cancer has become a prevalent malignant tumor, particularly papillary thyroid carcinoma (PTC), constituting over 90% of cases. Most PTC lesions are asymptomatic and remain subclinical throughout life, and active surveillance is now being used to monitor the progression of these lesions and intervene when appropriate. This evidence synthesis aims to assess PTC progression in size over time during active surveillance in terms of PTC tumor size progression to or beyond 3 mm during the surveillance period.</p><h3>Methods</h3><p dir="ltr">A dose–response meta‐analysis was conducted using the robust error meta‐regression method, using time as the “dose” and cumulative progression (%) was assessed. A comprehensive literature review was done using PubMed/MEDLINE and EMBASE from inception till August 2024.</p><h3>Results</h3><p dir="ltr">A total of 21 studies from 7 different countries, including 14 648 participants, were included. Incident progression at 2 years of follow‐up was 1%, and this increased linearly to 12% at 20 years of follow‐up.</p><h3>Conclusion</h3><p dir="ltr">It was concluded that progression over the threshold increases linearly over time at approximately less than 1% per year. Therefore, size progression beyond the threshold occurs in a minority and in less than one eighth of subjects by two decades of follow‐up.</p><h2>Other Information</h2><p dir="ltr">Published in: Cancer Reports<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1002/cnr2.70183" target="_blank">https://dx.doi.org/10.1002/cnr2.70183</a></p>
eu_rights_str_mv openAccess
id Manara2_28b27dbdad84f9c7fdd20eb65e37ab6b
identifier_str_mv 10.1002/cnr2.70183
network_acronym_str Manara2
network_name_str Manara2
oai_identifier_str oai:figshare.com:article/30454559
publishDate 2025
repository.mail.fl_str_mv
repository.name.fl_str_mv
repository_id_str
rights_invalid_str_mv CC BY 4.0
spelling Size Increment During Surveillance in Papillary Thyroid Cancer: Evidence Synthesis and Dose–Response Meta‐AnalysisMohamed Badie Ahmed (10223510)Emad Naem (21363605)Harman Saman (16316283)Abeer Alsherawi (17945291)Asma Syed (14778826)Noora Al‐Abdulla (22502162)Latifa Alkaabi (22502165)Mahmoud A. Zirie (19421317)Suhail A. Doi (9552474)Biomedical and clinical sciencesMedical biochemistry and metabolomicsOncology and carcinogenesisHealth sciencesEpidemiologyactive surveillancedose–response meta-analysispapillary thyroid cancertumor progression<h3>Introduction</h3><p dir="ltr">Differentiated thyroid cancer has become a prevalent malignant tumor, particularly papillary thyroid carcinoma (PTC), constituting over 90% of cases. Most PTC lesions are asymptomatic and remain subclinical throughout life, and active surveillance is now being used to monitor the progression of these lesions and intervene when appropriate. This evidence synthesis aims to assess PTC progression in size over time during active surveillance in terms of PTC tumor size progression to or beyond 3 mm during the surveillance period.</p><h3>Methods</h3><p dir="ltr">A dose–response meta‐analysis was conducted using the robust error meta‐regression method, using time as the “dose” and cumulative progression (%) was assessed. A comprehensive literature review was done using PubMed/MEDLINE and EMBASE from inception till August 2024.</p><h3>Results</h3><p dir="ltr">A total of 21 studies from 7 different countries, including 14 648 participants, were included. Incident progression at 2 years of follow‐up was 1%, and this increased linearly to 12% at 20 years of follow‐up.</p><h3>Conclusion</h3><p dir="ltr">It was concluded that progression over the threshold increases linearly over time at approximately less than 1% per year. Therefore, size progression beyond the threshold occurs in a minority and in less than one eighth of subjects by two decades of follow‐up.</p><h2>Other Information</h2><p dir="ltr">Published in: Cancer Reports<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1002/cnr2.70183" target="_blank">https://dx.doi.org/10.1002/cnr2.70183</a></p>2025-05-08T03:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1002/cnr2.70183https://figshare.com/articles/journal_contribution/Size_Increment_During_Surveillance_in_Papillary_Thyroid_Cancer_Evidence_Synthesis_and_Dose_Response_Meta_Analysis/30454559CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/304545592025-05-08T03:00:00Z
spellingShingle Size Increment During Surveillance in Papillary Thyroid Cancer: Evidence Synthesis and Dose–Response Meta‐Analysis
Mohamed Badie Ahmed (10223510)
Biomedical and clinical sciences
Medical biochemistry and metabolomics
Oncology and carcinogenesis
Health sciences
Epidemiology
active surveillance
dose–response meta-analysis
papillary thyroid cancer
tumor progression
status_str publishedVersion
title Size Increment During Surveillance in Papillary Thyroid Cancer: Evidence Synthesis and Dose–Response Meta‐Analysis
title_full Size Increment During Surveillance in Papillary Thyroid Cancer: Evidence Synthesis and Dose–Response Meta‐Analysis
title_fullStr Size Increment During Surveillance in Papillary Thyroid Cancer: Evidence Synthesis and Dose–Response Meta‐Analysis
title_full_unstemmed Size Increment During Surveillance in Papillary Thyroid Cancer: Evidence Synthesis and Dose–Response Meta‐Analysis
title_short Size Increment During Surveillance in Papillary Thyroid Cancer: Evidence Synthesis and Dose–Response Meta‐Analysis
title_sort Size Increment During Surveillance in Papillary Thyroid Cancer: Evidence Synthesis and Dose–Response Meta‐Analysis
topic Biomedical and clinical sciences
Medical biochemistry and metabolomics
Oncology and carcinogenesis
Health sciences
Epidemiology
active surveillance
dose–response meta-analysis
papillary thyroid cancer
tumor progression